These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 25924547)

  • 1. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.
    Boster AL; Ford CC; Neudorfer O; Gilgun-Sherki Y
    Expert Rev Neurother; 2015 Jun; 15(6):575-86. PubMed ID: 25924547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
    Johnson KP
    Expert Rev Neurother; 2012 Apr; 12(4):371-84. PubMed ID: 22449210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
    Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
    Ziemssen T; Calabrese P; Penner IK; Apfel R
    J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis.
    Ziemssen T; Ashtamker N; Rubinchick S; Knappertz V; Comi G
    Expert Opin Drug Saf; 2017 Feb; 16(2):247-255. PubMed ID: 27989217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis.
    Schipper HM; Arnold D; GrandʼMaison F; Melmed C; Moore F; Levental M; Su H; Constantin M; Stril JL; Godin J
    Clin Neuropharmacol; 2015; 38(4):127-31. PubMed ID: 26166235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.
    Wolinsky JS; Borresen TE; Dietrich DW; Wynn D; Sidi Y; Steinerman JR; Knappertz V; Kolodny S;
    Mult Scler Relat Disord; 2015 Jul; 4(4):370-6. PubMed ID: 26195058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
    McKeage K
    CNS Drugs; 2015 May; 29(5):425-32. PubMed ID: 25906331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate therapy for multiple sclerosis: a review.
    Perumal J; Filippi M; Ford C; Johnson K; Lisak R; Metz L; Tselis A; Tullman M; Khan O
    Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):1019-29. PubMed ID: 17125414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
    Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
    Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
    Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I
    BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients.
    Schreiber H; Hipp J; Roßnagel F; Moritz C
    Neurodegener Dis Manag; 2023 Oct; 13(5):281-288. PubMed ID: 37909320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of endermology on indurations and panniculitis/lipoatrophy during relapsing-remitting multiple sclerosis long-term treatment with glatiramer acetate.
    Márquez-Rebollo C; Vergara-Carrasco L; Díaz-Navarro R; Rubio-Fernández D; Francoli-Martínez P; Sánchez-De la Rosa R
    Adv Ther; 2014 Aug; 31(8):904-14. PubMed ID: 25047757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing-Remitting Multiple Sclerosis.
    Singhal T; Tauhid S; Hurwitz S; Neema M; Bakshi R
    J Neuroimaging; 2017 Jan; 27(1):33-36. PubMed ID: 27466943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M;
    Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
    Ramtahal J; Jacob A; Das K; Boggild M
    J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.
    Qizilbash N; Mendez I; Sanchez-de la Rosa R
    Clin Ther; 2012 Jan; 34(1):159-176.e5. PubMed ID: 22284996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.
    Rovaris M; Comi G; Rocca MA; Wolinsky JS; Filippi M;
    Brain; 2001 Sep; 124(Pt 9):1803-12. PubMed ID: 11522582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.